--- title: "Idiopathic Short Stature BioMarin 111-210 | Sutter Health" description: "A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature" url: "https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Idiopathic Short Stature BioMarin 111-210 # Idiopathic Short Stature 111-210 **Status:** Closed to Enrollment #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06382155?term=BioMarin%20111-210&rank=1). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). TEMPORARILY CLOSED TO ENROLLMENT The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS). Following a minimum 6 month observational period in which baseline growth is assessed, participants in the vosoritide and placebo groups will complete a minimum of 6 months of randomized treatment (maximum of 6 months of placebo treatment), followed by open-label treatment with vosoritide until they reach near-final adult height, or at least 16 years of age for females or 18 years of age for males, whichever comes later. Participants randomized to the hGH group will receive open-label hGH for a minimum of 4 years. ![Gnanagurudasan Prakasam, M.D.](https://dyn.mktgcdn.com/p/KZGsi4wXLoBlX4kBmYnknAZObscPAn1UC-XvgSdnKIY/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Gnanagurudasan Prakasam, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/gnanagurudasan-prakasam-md-1049681012) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Congenital Adrenal Hyperplasia in Pediatrics CRN04894-13](https://www.sutterhealth.org/research/clinical-trials/congenital-adrenal-hyperplasia-in-pediatrics-crn04894-13-2068022648) A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension **Status:** Coming Soon - Clinical trial ### [Hypothyroidism M21-341 AVANTI](https://www.sutterhealth.org/research/clinical-trials/hypothyroidism-m21-341-avanti-1095733783) A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism **Status:** Open to Enrollment - Clinical trial ### [Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY](https://www.sutterhealth.org/research/clinical-trials/diabetes-type-ii-pediatric-achieve-peds-j2a-mc-gzgy-2084630060) A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes **Status:** Coming Soon - Clinical trial ### [Growth Hormone Deficiency (GHD) LUM-201-10 OraGrowth](https://www.sutterhealth.org/research/clinical-trials/growth-hormone-deficiency-ghd-lum-201-10-oragrowth-2044047443) A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD) **Status:** Open to Enrollment - Clinical trial ### [Idiopathic Short Stature ASND0047 HighLiGHts](https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-asnd0047-highlights-2059403614) A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents With Growth Failure or Short Stature Due to Growth Hormone Sufficient Disorders - Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Idiopathic Short Stature BioMarin 111-210"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937#medicalwebpage","name":"Idiopathic Short Stature 111-210","description":"A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature","url":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937","inLanguage":"en-US","dateModified":"2026-09-11","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937#breadcrumblist"},"mentions":[{"@type":"Person","name":"Gnanagurudasan Prakasam, M.D.","url":"https://www.sutterhealth.org/research/investigators/gnanagurudasan-prakasam-md-1049681012","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937#medicaltrial","name":"Idiopathic Short Stature 111-210","alternateName":"A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature","url":"https://www.sutterhealth.org/research/clinical-trials/idiopathic-short-stature-biomarin-111-210-1095733937","description":"TEMPORARILY CLOSED TO ENROLLMENT The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS). Following a minimum 6 month observational period in which baseline growth is assessed, participants in the vosoritide and placebo groups will complete a minimum of 6 months of randomized treatment (maximum of 6 months of placebo treatment), followed by open-label treatment with vosoritide until they reach near-final adult height, or at least 16 years of age for females or 18 years of age for males, whichever comes later. Participants randomized to the hGH group will receive open-label hGH for a minimum of 4 years.","identifier":"NCT06382155","code":{"@type":"MedicalCode","codeValue":"NCT06382155","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06382155?term=BioMarin%20111-210&rank=1","status":"https://schema.org/ActiveNotRecruiting","studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```